Stryker snaps up ENT-device maker Entellus Medical in $662M deal

Stryker snaps up ENT-device maker Entellus Medical and its Latera absorbable nasal implant device in $662M deal.

Michigan-based device giant Stryker acquired Entellus Medical, the maker of minimally invasive devices for the treatment of airway obstructions, in a deal worth about $662 million. The deal is pending Entellus shareholder and regulatory approval.

Stryker offered Entellus $24 a share, which equates to about a 50% premium over the closing price of its stock Wednesday. It said the deal for Entellus would likely be dilutive to its 2018 adjusted net earnings per diluted share by 4 cents, and then accretive thereafter.

Entellus offers the Latera absorbable nasal implant device that rests along the nasal wall to support the upper and lower cartilage in the nose. The Latera device moved to Entellus in July when the company shelled out $81 million to acquire Spirox. It was the biggest deal for Entellus in its 11-year history.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Entellus is a leader in the ENT segment and offers a comprehensive portfolio of products that enable physicians to conveniently and comfortably perform a broad range of ENT procedures,” Timothy J. Scannell, a Stryker group president, said in a statement.

In June, Stryker acquired Novadaq, which specializes in fluorescence imaging systems with the goal of improving quality of care and reducing healthcare costs, for $701 million. Novadaq’s Spy Imaging Systems are CE-marked and cleared in the U.S. and Canada. The Spy Elite device allows surgeons conducting open procedures, such as cardiothoracic surgery and gastrointestinal surgery, to visualize blood flow and tissue perfusion in real time.

Suggested Articles

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.